FDA proposes biggest TRT label change since 2015 — age limit gone, prostate cancer language narrowed, BPH warning revised.

What HHS and FDA actually proposed

On June 18, 2026, HHS announced through the FDA that manufacturers of approved testosterone-therapy products should update their prescribing information based on a review of new clinical evidence and existing data (HHS). This announcement follows a February 2025 FDA action that removed the boxed cardiovascular warning from testosterone products after review of the TRAVERSE trial (FDA class-wide labeling changes, Feb 2025), a December 2025 FDA expert panel that called for further labeling revisions (STAT), and a public-comment period that closed in early 2026.

Three distinct changes are on the table in the June 18 proposal:

• Age-related hypogonadism. Remove the “limitation of use” language stating that safety and effectiveness of TRT have not been established in men with age-related hypogonadism.
• Prostate cancer. Narrow the formal contraindication so it applies only to men with metastatic prostate cancer, and revise the warning language on prostate cancer risk to reflect that clinical trial and epidemiologic evidence has not generally shown TRT to increase prostate cancer risk.
• BPH (enlarged prostate). Revise the current warning language, which advises that TRT may worsen BPH symptoms, to reflect that the FDA's review did not find worsening of symptoms in men with mild-to-moderate BPH. Men with severe symptoms are still expected to be closely monitored (Healthline coverage).

The age-related hypogonadism limitation

Since 2015, every FDA-approved testosterone product has carried some version of this language: the safety and effectiveness of testosterone replacement therapy in men with age-related hypogonadism have not been established. That single sentence has shaped a decade of clinical practice, insurance coverage, and telehealth prescribing. It's the reason most TRT prescriptions to men over 40 have been technically off-label, and the reason many primary care physicians hesitated to prescribe testosterone even to men with clearly symptomatic low-T backed by bloodwork (Translational Andrology and Urology, historical review).

The FDA now says, based on its review of the TRAVERSE trial and other evidence, that the limitation is no longer scientifically warranted (HHS; AOL summary of the proposal). What the removal does not do is create a blanket age-based indication. Eligibility still requires documented low testosterone on bloodwork plus symptoms — the label change removes the categorical exclusion, not the clinical gatekeeping.

Prostate cancer language, narrowed

Current TRT labels generally advise against use in men who have or may have prostate cancer and warn that therapy could raise the risk of developing it. Under the June 18 proposal, TRT would be formally contraindicated only in men with metastatic prostate cancer — cancer that has spread beyond the prostate itself (AOL; Healthline).

The FDA stated that available clinical trial and epidemiologic evidence has not generally shown an increased risk of prostate cancer among men receiving testosterone therapy. The revised label would still require providers to evaluate a patient's prostate cancer risk, perform appropriate screening before starting treatment, and monitor during therapy (HHS).

The FDA also acknowledged that some uncertainty remains because prostate cancer can develop slowly and existing studies may not be long enough to detect very long-term effects (AOL). Screening and monitoring are still expected — the change is in how the label characterizes risk, not in the standard of care.

BPH warning, revised

Benign prostatic hyperplasia — enlarged prostate — has for years carried a warning that testosterone therapy may worsen urinary symptoms. The FDA's review found that available clinical trial data does not generally show worsening of symptoms in men with mild-to-moderate BPH. The revised labeling would still recommend that men with severe symptomatic disease be closely monitored (Healthline; AOL).

Practically, this changes how the label reads more than how careful clinicians already practice. Men on TRT with moderate-to-severe LUTS (lower urinary tract symptoms) have long been monitored with symptom scales, PSA, and post-void residual volumes where clinically indicated — and that will continue.

The evidence base behind the proposal

Three inputs did the heavy lifting:

1. TRAVERSE trial. The Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men trial randomized 5,246 men aged 45–80 with pre-existing or high risk of cardiovascular disease. After a mean follow-up of about 33 months, the incidence of major adverse cardiovascular events (MACE) with TRT was non-inferior to placebo — 7.0% versus 7.3% (HR 0.96; 95% CI 0.78 to 1.17). Prostate cancer incidence was also not significantly different between groups. These findings, published in the New England Journal of Medicine in 2023, drove the FDA's February 2025 removal of the boxed cardiovascular warning (FDA class-wide labeling changes; Urology Times, Dec 2025 FDA panel coverage).
2. December 2025 FDA expert panel. On December 10, 2025, the FDA convened an expert panel on TRT labeling. Panelists — including urology and sexual-medicine specialists — recommended that the age-related hypogonadism limitation be removed, that the prostate cancer contraindication be narrowed, and that testosterone's Schedule III designation be reconsidered (STAT; Urology Times).
3. April 2026 Federal Register notice. The FDA published a notice soliciting sponsors interested in pursuing a new indication for testosterone in men with low libido and idiopathic hypogonadism — a signal that the agency saw the existing evidence base as sufficient to open formal regulatory pathways beyond just label revision (FDA press announcement, April 16, 2026).

None of that erases the fact that the TRAVERSE trial also identified a small increase in blood pressure and a slightly higher incidence of atrial fibrillation in the TRT arm (Healthline, Dec 2025). Those signals are why the current labels still carry a blood-pressure warning and why serious TRT programs still measure blood pressure at intake and follow-up. Removing the age-related limitation and narrowing the prostate cancer contraindication does not remove those other clinical realities.

Where the proposal stands now

As of publication, HHS and FDA have requested that manufacturers of approved testosterone products submit updated prescribing information. The June 18 announcement is the formal request; the FDA has not yet published a final, class-wide label as a rule. Independent legal and regulatory commentary — including Global Relay's regulatory summary — characterizes the action as a manufacturer-directed request following a multi-year review, not an immediate class-wide label rewrite.

Practically, that means:

• The current labels for testosterone products are still what they were before June 18. Manufacturers need to file updated prescribing information for each product, and the FDA has to accept it, before physical labeling changes.
• Clinical guidelines from major societies — EAU Sexual and Reproductive Health Guidelines, 2026 update included — remain the operative standard-of-care documents alongside the label. The 2026 EAU update, released July 30, 2026, revised the hypogonadism section and specifically restructured guidance around prostate cancer topics.
• DEA scheduling is untouched. Testosterone remains a Schedule III controlled substance. The December 2025 FDA panel recommended reconsidering the schedule; the June 18 HHS action did not act on that recommendation.

What this means for Aurafil patients

Honestly and specifically: the way Aurafil evaluates and treats men has not changed as of today.

• We already require documented low testosterone on morning bloodwork plus symptoms before starting TRT. The proposed label change removes a regulatory exclusion; it does not lower the clinical bar we hold ourselves to.
• We already screen for prostate cancer risk with PSA and history at intake, and monitor PSA on therapy. That does not change with the proposed label. Men with any active prostate cancer treatment or metastatic disease are not candidates.
• We already measure blood pressure and hematocrit at intake and follow-up. The 2025 boxed-warning removal did not remove those clinical signals from the label, and this proposal does not either.
• For men who were told years ago that TRT wasn't an option because of their age or a family history of prostate concerns — a proposal like this is one more indicator that the categorical version of that advice is out of step with the current evidence base. Whether treatment is right for you is still an individual clinical decision based on labs, symptoms, and your personal risk profile.
• We will not oversell what this proposal is. It is a proposed label change, not a new indication and not a guarantee of insurance coverage. When and if the FDA formalizes updated labeling, we will update this page and any patient-facing material that references the old restrictions.

The high-level point is simple: the FDA is catching up to what the evidence has been showing for several years — that appropriately screened, appropriately monitored testosterone therapy in men with documented low-T and symptoms is a legitimate treatment, including in men whose low-T is best characterized as age-related. That has been the working position of thoughtful men's health clinicians for a while. It's the working position of Aurafil today.